Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind?

The tandem launches of two gene therapies for sickle cell disease will likely be critical to determining whether and how US reimbursement policies can shape commercial success for hugely expensive, one-time treatments. Bluebird is the smaller, less-experienced company up against Vertex – but argues it has more relevant experience.

gene therapy reimbursement
Simultaneous approvals are putting a spotlight on gene therapy reimbursement. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The tandem launches of the first gene therapies to treat sickle cell disease will be an important test of the US reimbursement system for one-time gene therapies.

Vertex Pharmaceuticals Incorporated’s Casgevy and bluebird bio’s Lyfgenia are not the first multi-million-dollar, one-time treatments to enter the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By 

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By 

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By 

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By 

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By 

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By 

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.